Skip to Content
Merck
  • Advanced glycation end products as a source of artifacts in immunoenzymatic methods.

Advanced glycation end products as a source of artifacts in immunoenzymatic methods.

Glycoconjugate journal (2018-01-07)
Aleksandra Kuzan, A Chwiłkowska, K Maksymowicz, A Bronowicka-Szydełko, K Stach, C Pezowicz, A Gamian
ABSTRACT

The most abundant proteins in the arteries are those of extracellular matrix, ie. collagen and elastin. Due to their long half-lifes these proteins have an increased chance to undergo glycation. The aim of this study was to determine relationship between the content of the main extracellular matrix proteins and the advanced glycation end products (AGEs) in arteries. In this study 103 fragments of aorta were analyzed by ELISA and immunobloting for the content of collagens type I, III and IV and elastin and the content of advanced glycation end-products (AGE). A negative correlation between the content of collagens type III and IV and AGE (r = -0,258, p = 0,0122, and a weak negative correlation between collagen type III and age of the sample donor (r = 0,218, p = 0,0262) were demonstrated. This result comes as a surprise and it contradicts an intuitive assumption that with more glycation substrate, i.e. matrix proteins, more AGE products are expected. We have concluded that the results of the ELISA tests must have been influenced by the glycation. As a consequence, either modified protein molecules were not being recognized by the antibodies, or the glycation, and formation of crosslinks have blocked access of the antibodies to the antigen. It will conceal the effect of the linear dependence between the result (absorbance/densitometry) from the quantity of protein to which the antibody is directed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Collagen, Type III antibody produced in mouse, clone FH-7A, ascites fluid
Sigma-Aldrich
Monoclonal Anti-Collagen, Type IV antibody produced in mouse, clone COL-94, ascites fluid